Chris SheldonVP, Global Head, Business Development & Licensing, Oncology R&D at AstraZeneca
Chris has worked in the UK at AstraZeneca (AZ) for over 16 years and is currently Vice President & Head of Oncology Business Development in AZ’s Oncology Research & Development Unit. Chris and his team are responsible for the scouting of all new oncology technologies and leading the technical evaluation of such new M&A, in-licensing, out-licensing (divestment) and collaboration targets in all stages of oncology development as well as academic collaborations and early stage transactions/alliance management. Most recently, he led the evaluation of AstraZeneca’s major $6.9bn co-development/co-promotion deal with Daiichi-Sankyo for trastuzumab deruxtecan (DS-8201) an antibody drug conjugate. Previously Chris led both AZ’s majority $4 billion stake investment in Acerta Pharma for acalabrutinib, a potential best-in-class BTK inhibitor in haematology and a $1.275bn immuno oncology collaboration deal with innate Pharma for monalizumab a novel NKG2A inhibitor. Chris has also evaluated and executed over a dozen novel combination collaboration deals for AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab), best-in-class EGFR inhibitor Tagrisso (osimertinib) and first-in-class SERD Faslodex (fulvestrant). Prior to this Chris worked as Head of Oncology Search & Evaluation in AZ’s Strategy team in its Oncology Business Unit (OBU) covering clinical stage opportunities as well as in early stage oncology business development roles and was involved in all aspects of evaluation, due diligence and negotiation of deals. Before his business development career, Chris worked in discover research at AstraZeneca as a senior research chemist. He also holds a Ph.D. in chemistry from the University of Bristol, UK and a first class honours degree from the University of Sheffield, UK.